Bladder Cancer

Keytruda, Tecentriq Labeling Updated to Limit Use in Urothelial Cancer

Keytruda, Tecentriq Labeling Updated to Limit Use in Urothelial Cancer

The updates come after the Agency made the decision to limit the use of these agents as monotherapy in patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).

Radical Cystectomy Offers Better Survival vs Trimodal Therapy

Radical Cystectomy Offers Better Survival vs Trimodal Therapy

Bladder preservation for MIBC is associated with a higher mortality rate and greater costs compared with radical cystectomy.

Robotic, Open Cystectomy Offer Comparable Bladder Cancer Outcomes

Robotic, Open Cystectomy Offer Comparable Bladder Cancer Outcomes

By

In a randomized study, patients who underwent robotic-assisted and open radical cystectomy had similar 2-year progression survival rates.

Gender Difference in Survival Seen After Radical Cystectomy

Gender Difference in Survival Seen After Radical Cystectomy

Females have worse disease-free, cancer-specific, overall survival versus males with bladder cancer.

Robotics Involved in Most Urologic Cancer Surgeries

Robotics Involved in Most Urologic Cancer Surgeries

By

In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.

Urothelial Cell Carcinoma Linked to High Albumin Excretion

Urothelial Cell Carcinoma Linked to High Albumin Excretion

By

Patients in the highest quintile of urinary albumin excretion had a 4.5-fold increased risk of urothelial cell carcinoma vs those in quintiles 1-3.

Blue Light Cystoscopy Enhances Detection of Cancerous Bladder Lesions

Blue Light Cystoscopy Enhances Detection of Cancerous Bladder Lesions

By

Real-world study confirms the improved sensitivity of blue light vs white light cystoscopy (91% vs 79%) for detecting bladder cancer.

Neoadjuvant Chemo vs TUR Before RC Ups Survival

Neoadjuvant Chemo vs TUR Before RC Ups Survival

By

Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.

Neoadjuvant vs Adjuvant Chemo Ups MIBC Patient Survival

Neoadjuvant vs Adjuvant Chemo Ups MIBC Patient Survival

By

The 5-year overall survival rate is significantly higher among radical cystectomy patients who receive neoadjuvant vs adjuvant chemotherapy, study finds.

Aspirin Use Prior to Radical Cystectomy Linked to Improved Survival

Aspirin Use Prior to Radical Cystectomy Linked to Improved Survival

By

Daily use of aspirin before radical cystectomy is associated with a significant 36% and 30% decreased risk of cancer-specific and all-cause mortality.

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

By

A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.

UroVysion Results Predict Post-BCG Bladder Cancer Outcomes

UroVysion Results Predict Post-BCG Bladder Cancer Outcomes

By

Positive results before BCG treatment and at the 6-week instillation are associated with an increased likelihood of disease recurrence and/or progression.

Predictors of Post-cystectomy C. difficile Infection Identified

Predictors of Post-cystectomy C. difficile Infection Identified

By

Female sex and need for a blood transfusion are associated with development of Clostridium difficile infection following radical cystectomy.

Radical Cystectomy for MIBC Offers Better Survival vs Chemoradiation

Radical Cystectomy for MIBC Offers Better Survival vs Chemoradiation

By

Large study reveals a significant 15% survival advantage associated with radical cystectomy vs chemoradiation therapy.

Developments in the Management of BCG-Unresponsive NMIBC

Developments in the Management of BCG-Unresponsive NMIBC

Novel immunotherapies and chemotherapies hold promise as non-surgical salvage options.

PPD Skin Test Enhances BCG Therapy in Bladder Cancer

PPD Skin Test Enhances BCG Therapy in Bladder Cancer

Enhanced therapeutic effect of bacillus Calmette-Gurin tx in non-muscle invasive bladder cancer.

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

Smoking Ups Bladder Cancer Risk, Lowers Prostate Cancer Risk

By

Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.

Post-op Intravesical Gemcitabine May Lower Bladder CA Recurrence Risk

Post-op Intravesical Gemcitabine May Lower Bladder CA Recurrence Risk

By

Instilling gemcitabine into the bladder immediately following resection of low-grade non-muscle-invasive bladder cancer significantly lowers recurrence risk.

Urinary Cytology and Biomarkers in NMIBC: What's New?

Urinary Cytology and Biomarkers in NMIBC: What's New?

Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance.

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer

One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.

Non-Invasive Test for Urothelial Cancer Detection

Non-Invasive Test for Urothelial Cancer Detection

When combined with cytology, UroSEEK detected 95% of patients who developed bladder cancer

Bladder Cancer Mortality in Men Lower With 5-ARI Use

Bladder Cancer Mortality in Men Lower With 5-ARI Use

By

Use of 5-alpha-reductase inhibitors before and after diagnosis of the malignancy is associated with a 15% and 22% decreased risk of bladder cancer mortality, respectively.

Advanced CKD Linked to Worse Radical Cystectomy Outcomes

Advanced CKD Linked to Worse Radical Cystectomy Outcomes

By

In multivariable analyses, CKD stage G3b or higher was significantly associated with worse progression-free and cancer-specific survival.

Model Predicts Survival in Urothelial Cancer With Immunotherapy

Model Predicts Survival in Urothelial Cancer With Immunotherapy

Model, based on 6 factors, predicts overall survival for patients treated with atezolizumab

Active Surveillance Reasonable for NMIBC

Active Surveillance Reasonable for NMIBC

Appears to be a cost-effective strategy for patients with small size, stage pTa or pT1a recurrent tumors

Atezolizumab Safe, Beneficial Long-Term in mUC

Atezolizumab Safe, Beneficial Long-Term in mUC

By

In a 3-year study, toxic effects of atezolizumab remained manageable and responses durable.

Biopsy, Pathology Results Often Differ in UTUC

Biopsy, Pathology Results Often Differ in UTUC

By

Study results serve as a caution against relying on ureteroscopic biopsy to establish tumor grade and stage, researchers say.

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

By

Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.

Urologic Cancer Surgery Readmission Rate Highest for RC

Urologic Cancer Surgery Readmission Rate Highest for RC

By

In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

E-Cigarette Smoke Possibly Carcinogenic to Lung, Bladder

E-Cigarette Smoke Possibly Carcinogenic to Lung, Bladder

Nicotine and nicotine-derived nitrosamine ketone enhance mutational susceptibility in human cells.

Sign Up for Free e-newsletters